Results 51 to 60 of about 6,610 (157)

Targeted Delivery of mRNA to the Heart via Extracellular Vesicles or Lipid Nanoparticles

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
ABSTRACT Efficient and specific delivery of mRNA to target tissues is critical for maximising therapeutic benefits while minimising off‐target effects and systemic toxicity. Systemic administration of mRNA using lipid nanoparticles (LNPs) or extracellular vesicles (EVs) typically leads to predominant accumulation in the liver.
Muhammad Nawaz, Benyapa Tangruksa, Sepideh Heydarkhan‐Hagvall, Franziska Kohl, Hernán González‐King Garibotti, Yujia Jing, Zahra Payandeh, Azadeh Reyahi, Karin Jennbacken, John Wiseman, Leif Hultin, Lennart Lindfors, Jane Synnergren, Hadi Valadi   +13 more
wiley   +1 more source

Breaking the Heat Tolerance Response: The Crucial Role of MFAP4 in Combating Heat‐Induced Cardiac Injury

The FASEB Journal, Volume 40, Issue 10, 31 May 2026.
MFAP4 deficiency exacerbates heatstroke outcomes, accelerating hyperthermia, delaying recovery, reducing survival, and worsening cardiac injury. Conversely, MFAP4 overexpression enhances cellular thermoresistance. MFAP4 orchestrates transcriptional reprogramming in response to HS.
LiJun Fan, MingXiao Song, QingHan Zhang, ZiYi Guo, Jing Wang, XueWei Chen, ChenYi Hu, JunYu Lu, ZhuGe Xi   +8 more
wiley   +1 more source

Successful Hemostasis with Recombinant Activated Factor VII in a Patient with Massive Hepatic Subcapsular Hematoma

Case Reports in Gastroenterology, 2009
Recombinant activated coagulation factor VII (rFVIIa) is known to be effective in the management of acquired deficiencies of factor VII and platelet function defects.
Ju-Hee Lee, Hee Bok Chae, Eui-Keun Seo, Won Joong Jeon, Hye Won Jeong, Yoon Mi Shin, Jang Whan Bae, Soon Kil Kwon, Il Hun Bae, Woo Sub Shim, Dong Ick Shin, Rohyun Sung, Ji Yoon Kim   +12 more
doaj   +1 more source

Atrophic Skeletal Muscle‐Derived Extracellular Vesicles Transfer miR‐125a‐5p to Inhibit Bone Formation in Osteoporosis during Aging

Advanced Science, Volume 13, Issue 25, 4 May 2026.
A muscle‐bone endocrine pathway in aging is revealed in which extracellular vesicles released from atrophic skeletal muscle (Aged‐SKM‐EVs) inhibit bone formation. These EVs deliver miR‐125a‐5p to osteoblasts, thereby suppressing the SIRT7‐Sp7 signaling axis and osteogenic differentiation.
Xiaoyan Shao, Pan Zhang, Zhidan Fan, Jiaquan Lin, Xiang Chen, Na Liu, Wang Gong, Yi He, Yining Zhou, Tianshu Shi, Yong Shi, Yuze Ma, Wentian Gao, Haosheng Wang, Depeng Fang, Chengzhi Wang, Wenshu Wu, Wenjin Yan, Jianghui Qin, Dongyang Chen, Haiguo Yu, Qing Jiang, Baosheng Guo   +22 more
wiley   +1 more source

Overview of the use of recombinant factor VIIa in children

Pediatric Health, Medicine and Therapeutics, 2014
John Puetz Department of Pediatrics, Division of Hematology/Oncology, Cardinal Glennon Children's Medical Center, Saint Louis University, St Louis, MO, USA Abstract: Recombinant factor VIIa (rFVIIa) was initially developed as a bypassing agent to ...
Puetz J
doaj  

Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding

BMC Infectious Diseases, 2007
Background This report discusses a case of unsuccessful treatment with recombinant factor VIIa (rFVIIa) in off-label use. The need for international guidelines concerning the off-label use of rFVIIa is outlined as well as the need for methods to control ...
Tsakiris Dimitrios A, Weisser Maja, Conen Anna, Siegemund Martin   +3 more
doaj   +1 more source

Management of a twin pregnancy patient with Glanzmann thrombasthenia might be caused by a novel ITGA2B gene mutation (c.2822G>A): a case report and family investigation

Platelets
Mutations in the ITGA2B or ITGB3 gene that encodes for the αIIbβ3 platelet integrin usually cause Glanzmann thrombasthenia (GT). This study aims to investigate the clinical characteristics of a pedigree exhibiting an inherited hemorrhagic disorder ...
Xiangcheng Liao, Ruikai Zhu, Zhigang Yang, Aiqiu Qin, Yucong Huang, Ping Li, Liling Liu, Zhuning Mo   +7 more
doaj   +1 more source

Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions

The Turkish Journal of Pediatrics, 2003
Transfusion of platelet concentrates remains the first-line therapy for Glanzmann thrombasthenia in case of bleeding or preparation for surgery. However, development of antibodies to platelet glycoprotein (Gp) IIb/IIIa complex or human leukocyte ...
Omer Devecioğlu, Ayşegül Unüvar, Sema Anak, Ilmay Bilge, Haluk Ander, Orhan Ziylan   +5 more
doaj  

Use of Recombinant Activated Factor VIIa in a Six-Month-Old Child Due to Massive Hemorrhage During Elective Surgery for Choroid Plexus Carcinoma: Case Report

Acta Clinica Croatica, 2015
We present the use of recombinant activated factor VIIa (rFVIIa) in a 6-month-old infant that suffered massive bleeding and subsequent coagulation disturbances during elective surgery for choroid plexus carcinoma in the lateral ventricle.
Alenka Spindler Vesel, Vesna Novak-Jankovič, Branka Maldini, Neva Požar Lukanović, Kata Denić, Jasmina Markovič-Božič, Maja Šoštarič   +6 more
doaj  

A Patient with a Prolonged Activated Partial Thromboplastin Time and a Deep Intracerebral Haemorrhage

Case Reports in Neurology, 2012
We report on a 57-year-old woman with a pontine haemorrhage and an extremely prolonged activated partial thromboplastin time (aPTT) of more than 240 s, suggestive of a coagulation disorder.
Roger K. Schindhelm, Mariëlle J. Wondergem, Joke Admiraal, Gert Nap, Edwin ten Boekel, Lahcen Hani   +5 more
doaj   +1 more source